Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum BioVaxys Technology Corp. BVAXF


Primary Symbol: C.BIOV

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical... see more

CSE:BIOV - Post Discussion

BioVaxys Technology Corp. > BIOV 3.8 MILLION~THAT VOLUME WAS NOT CUZ OF DEBT NEWS$$
View:
Post by moneywagon on Oct 27, 2022 10:01am

BIOV 3.8 MILLION~THAT VOLUME WAS NOT CUZ OF DEBT NEWS$$

TRUST ME!!! that volume yesterday HAD NOTHING to do with debt news!! Brokers are positioning their MONEY and so you should be doing the same thing!! simple dimple.

The news affirms direction of momentum, progress and share price, which brings confidence to Brokers BIOV is going to embark on revenues$$$
but the volume is awarded to the hard work accomplished BIOV.

Are hands are tied we are FDA mercy...... and I repeat I wonder if INSIDERS are in "blackout"??
Nobody knows ???hmmmmmm

Close Prices Last 3 Months

Date Ex Sym Open High Low Close Chg Total Vol #Tr Bid Ask C-CSE U-NEO ATS A-Alpha O-Omega P-Pure X-Chi-X H-CX2 D-CXD L-LiquidNet M-TriAct I-Instinet Y-Lynx
2022-10-26 C BIOV 0.23 0.25 0.195 0.24 0.015 3,842,160 767 0.23 0.25 1,171,553 2,437,500   214,000     18,500     397    
2022-10-25 C BIOV 0.21 0.24 0.21 0.225 0.025 347,748 100 0.225 0.24 156,523 52,000   71,500           3,481    
2022-10-24 C BIOV 0.21 0.23 0.185 0.20 -0.02 450,829 127 0.20 0.22 249,404 137,000   53,500     10,000     529    
2022-10-21 C BIOV 0.22 0.23 0.195 0.22 0.01 537,870 144 0.21 0.22 329,821 162,000   32,500   2,000 9,500     1,364    
2022-10-20 C BIOV 0.205 0.25 0.205 0.21 0.005 794,211 244 0.21 0.24 506,416 209,500   50,500   10,500 15,200     2,095    
2022-10-19 C BIOV 0.16 0.21 0.16 0.205 0.05 1,456,357 327 0.205 0.21 752,955 575,500   103,500     19,000     5,202    
2022-10-18 C BIOV 0.14 0.185 0.13 0.16 0.02 553,352 190 0.15 0.175 299,965 130,500   93,000   10,500 18,000     1,049    
2022-10-17 C BIOV 0.17 0.17 0.13 0.145 -0.03 556,601 217 0.135 0.15 230,208 222,500   59,000   5,000 36,000     2,433    
2022-10-14 C BIOV 0.18 0.18 0.165 0.18   172,940 58 0.17 0.185 48,943 79,000   44,000   500       497    
2022-10-13 C BIOV 0.19 0.20 0.15 0.185   656,958 167 0.175 0.185 328,345 257,500   65,000   500 4,257     1,356    
2022-10-12 C BIOV 0.22 0.22 0.17 0.185 -0.035 479,860 178 0.18 0.20 278,611 92,500   99,000   2,000 5,000     2,241    
2022-10-11 C BIOV 0.225 0.255 0.215 0.22 -0.01 917,722 276 0.22 0.23 495,674 231,000   140,500   6,000 25,500     18,652    
2022-10-07 C BIOV 0.17 0.255 0.145 0.23 0.055 1,889,019 421 0.225 0.25 1,343,232 312,000   143,000   45,898 41,500     2,523    
2022-10-06 C BIOV 0.215 0.27 0.17 0.175 -0.03 2,243,372 678 0.17 0.18 1,308,886 602,000   267,000   8,500 49,500     6,086    
2022-10-05 C BIOV 0.12 0.21 0.115 0.205 0.10 1,296,692 354 0.205 0.22 840,822 306,500   83,000   5,000 57,103     4,267
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities